Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been assigned a consensus rating of “Buy” from the five ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $21.50.
ANGO has been the subject of several analyst reports. BidaskClub raised Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Zacks Investment Research raised Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research note on Tuesday, June 4th. TheStreet lowered Upland Software from a “b-” rating to a “c+” rating in a research note on Wednesday, July 10th. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.
In other news, Director Kevin J. Gould sold 13,650 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $21.45, for a total value of $292,792.50. Following the completion of the sale, the director now directly owns 61,774 shares of the company’s stock, valued at approximately $1,325,052.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.80% of the stock is owned by company insiders.
AngioDynamics stock traded down $0.34 during midday trading on Friday, reaching $21.19. 243,215 shares of the stock traded hands, compared to its average volume of 223,996. The business’s fifty day moving average price is $19.94. AngioDynamics has a 12 month low of $18.11 and a 12 month high of $25.48. The company has a market cap of $801.26 million, a PE ratio of 25.53 and a beta of 0.69. The company has a current ratio of 4.30, a quick ratio of 3.75 and a debt-to-equity ratio of 0.20.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). The firm had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. AngioDynamics’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.20 earnings per share. As a group, research analysts predict that AngioDynamics will post 0.27 EPS for the current fiscal year.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Further Reading: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.